It’s the GeneMedi’s summary page for Target/Biomarker Introduction of NAGLU. The page also collects GeneMedi’s different modalities and formats products for NAGLU in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the NAGLU target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Secreted Protein/Potential Cytokines.
This gene encodes an enzyme that degrades heparan sulfate by hydrolysis of terminal N-acetyl-D-glucosamine residues in N-acetyl-alpha-D-glucosaminides. Defects in this gene are the cause of mucopolysaccharidosis type IIIB (MPS-IIIB), also known as Sanfilippo syndrome B. This disease is characterized by the lysosomal accumulation and urinary excretion of heparan sulfate. [provided by RefSeq, Jul 2008]